• Product NameDRAK2 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationIon exchange chromatography purified
• ApplicationsELISA WB ICC
• Species ReactivityHu
• SpecificityIt has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable.
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a peptide corresponding to amino acids 351 to 365 of human DRAK2.
• Target NameDRAK2
• Accession No. Swiss-Prot:O94768
  Gene ID:9262
• UniprotO94768
• Gene ID9262;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

• Western blot analysis of DRAK2 in Jurkat (1,3) and Raji (2,4) cell lysate in the absence (1,2) or presence (3,4) of blocking peptide with DRAK2 antibody at 1:500 dilution.
• Immunocytochemistry of DRAK2 in Jurkat cells with DRAK2 antibody at 10 ug/mL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting